Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.

Mecenat is a digital marketplace that connects students, alumni, young professionals, and seniors with well-known brands by offering access to exclusive deals, career services, and relevant events. The Mecenat group operates in both Sweden and Finland, has approximately three million members, and collaborates with more than 700 local and global brands. Mecenat's platform spans various industries, including technology, fashion, travel and entertainment.

Vinge's team mainly consisted of Christina Kokko, Maria Dahlin Kolvik, Eléonore Friberg, Carl Fredrik Wachtmeister, Madelene Andersson, and Chris Bastholm (M&A), Victor Ericsson (Tax), Helena Göransson, Karl-Gustaw Tobola, August Ahlin, and Matilda Hamner (Banking and Finance), Ian Jonsson and Siri Blomberg (IP), Simon Söderholm and Linn Aho (Employment), Carla Håkansson and Hanna Kövamees (Commercial Agreements), Katja Häglund (GDPR), Hayaat Ibrahim (Compliance), Nils Unckel and Anton Sjökvist (AIFMD), Lovisa Lewin and Alva Chambert (Competition Law and FDI), and Caroline Löv (Transaction Support Coordinator).

For more information, please see the client's press release here. 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026